Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

PFI-1 (aka PF-6405761)

posted on Jun 26, 2018 02:52PM

Some talk on IV about Pfizer's PFI-1 compound because of a pre-clinical publication related to prostate cancer that was published this month. It's been around for several years now, but never started in any clinical trials as I can tell. Gilead, Abbvie, GSK are Zenith's main competitors in the BET inhibitor prostate cancer area right, all with ongoing clinical trials. I summarized some of the companies with ongoing BET programs here. Perhaps a big pharma w/o a current clinical BET inhibitor program, like Pfizer, would be very interested in buying Zenith?